When did OCULAR THERAPEUTIX INC (OCUL) report earnings last quarter?
OCULAR THERAPEUTIX INC (OCUL) last reported earnings on 2/5/2026.
NASDAQ:OCUL • US67576A1007
Past quarterly earnings results for OCULAR THERAPEUTIX INC (OCUL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.29 | -0.33 | 12.73% | - | 13.25M | 16.451M | -19.46% | -22.44% |
| Q3 2025 | -0.38 | -0.37 | -1.62% | -72.73% | 14.544M | 14.919M | -2.51% | -5.71% |
| Q2 2025 | -0.39 | -0.36 | -7.83% | -50.00% | 13.459M | 13.518M | -0.44% | -18.14% |
| Q1 2025 | -0.38 | -0.30 | -26.63% | 45.71% | 10.698M | 17.169M | -37.69% | -27.59% |
| Q4 2024 | -0.29 | -0.26 | -12.97% | 17.14% | 17.083M | 17.549M | -2.66% | 15.41% |
| Q3 2024 | -0.22 | -0.25 | 10.95% | -29.41% | 15.425M | 17.484M | -11.78% | 2.28% |
| Q2 2024 | -0.26 | -0.23 | -15.12% | - | 16.441M | 16.14M | 1.86% | 8.26% |
| Q1 2024 | -0.70 | -0.20 | -258.50% | -79.49% | 14.774M | 15.722M | -6.03% | 10.47% |
| Q4 2023 | -0.35 | -0.31 | -12.87% | -45.83% | 14.802M | 16.021M | -7.61% | 5.13% |
| Q3 2023 | -0.17 | -0.29 | 41.99% | 45.16% | 15.081M | 15.558M | -3.07% | 25.99% |
| Q2 2023 | -0.26 | -0.31 | 15.60% | -4.00% | 15.186M | 14.943M | 1.63% | 23.77% |
| Q1 2023 | -0.39 | -0.27 | -45.11% | -143.75% | 13.374M | 14.378M | -6.98% | 1.39% |
| Q4 2022 | -0.24 | -0.26 | 7.12% | -380.00% | 14.08M | 13.804M | 2.00% | 14.38% |
| Q3 2022 | -0.31 | -0.24 | -27.70% | -1,133.33% | 11.97M | 14.556M | -17.77% | -1.48% |
| Q2 2022 | -0.25 | -0.23 | -6.56% | -127.27% | 12.27M | 14.532M | -15.57% | 4.69% |
| Q1 2022 | -0.16 | -0.27 | 39.67% | -500.00% | 13.19M | 14.48M | -8.91% | 79.70% |
| Q4 2021 | -0.05 | -0.24 | 79.14% | 95.87% | 12.31M | 14.727M | -16.41% | 67.48% |
| Q3 2021 | 0.03 | -0.27 | 111.10% | 114.29% | 12.15M | 12.703M | -4.35% | 106.63% |
| Q2 2021 | -0.11 | -0.22 | 49.84% | 82.81% | 11.72M | 11.042M | 6.14% | 646.50% |
| Q1 2021 | 0.04 | -0.21 | 118.98% | 109.76% | 7.34M | 7.789M | -5.76% | 181.23% |
| Q4 2020 | -1.21 | -0.17 | -611.75% | - | 7.35M | 9.954M | -26.16% | - |
| Q3 2020 | -0.21 | -0.25 | 15.10% | - | 5.88M | 5.601M | 4.98% | - |
| Q2 2020 | -0.64 | -0.32 | -102.40% | - | 1.57M | 1.529M | 2.68% | - |
| Q1 2020 | -0.41 | -0.38 | -8.64% | - | 2.61M | 2.897M | -9.91% | - |
Notes
OCULAR THERAPEUTIX INC (OCUL) last reported earnings on 2/5/2026.
OCULAR THERAPEUTIX INC (OCUL) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, OCULAR THERAPEUTIX INC (OCUL) has beaten EPS estimates in 1 out of 4 releases.